| Presentation | Media | Date |
The Presentation on the NeuroRestore ACD856 publication: “Positive Allosteric Modulators of Trk Receptors for the Treatment of Alzheimer’s Disease” by Pontus Forsell et al from 2024, published in Pharmaceuticals (2024; 17(8), 997
|
|
|
December 20, 2024
|
CEO, Martin Jönsson at Redeye Theme Event Neurology
| |
|
December 3, 2024
|
AlzeCure's CEO Martin Jönsson presented at Aktiespararnas Stora Aktiedagarna in Stockholm (Swedish)
| |
|
November 27, 2024
|
CEO Martin Jönsson at Finwire - About the progress and in the future in Alzheimer's and pain. (Swedish)
| |
|
November 11, 2024
|
Poster from Ctad 2024 - Preclinical evidence for anti-inflammatory and immunomodulatory effects of NeuroRestore ACD856, a Trk-PAM in clinical development for the treatment of Alzheimer’s disease
|
| |
October 29, 2024
|
CEO, Martin Jönsson to presented at Redeye’s Neurology Day, Presentation about AlzeCure, our Alzheimer and pain platforms, projects, etc.
| |
|
October 23, 2024
|
ACD440 – A novel non-opioid analgesic – From AlzeCures live-event.
| |
|
October 23, 2024
|
ACD440 – A novel non-opioid analgesic, with Dr. Rolf Karlsten - AlzeCure´s live event.
| |
|
October 23, 2024
|
ACD440 – A novel non-opioid analgesic, with Märta Segerdahl, CMO and project manager - AlzeCure´s live event.
| |
|
October 23, 2024
|
Presentation about AlzeCure by CEO Martin Jönsson, presented at LSX Nordic Congress
| |
|
October 8, 2024
|
Interview with CEO Martin Jönsson and CSO Johan Sandin at Redeye about the ACD856 poster on an anti-inflammatory effect to be presented at CTAD, October 1, 2024 (Swedish)
| |
|
October 1, 2024
|
AlzeCures CEO, Martin Jönsson at Finwire (Swedish )
| |
|
August 27, 2024
|
Watch the latest interview at Redeye with our CEO, Martin Jönsson (Swedish)
| |
|
August 20, 2024
|
Alzecure’s pain project TrkA-NAM presented at the pain conference IASP, Augusti 5-9 2024 – Pharmalogical Effects of ACD137, a Potent and Selective Negative Allosteric Modulator of TrkA
|
| |
August 7, 2024
|
CEO Martin Jönsson presents at Redeye Investor forum (Swedish)
| |
|
May 16, 2024
|
Interview at Redeye with CEO, Martin Jönsson (Swedish)
| |
|
May 6, 2024
|
SITDOWN at Finwire - AlzeCures CEO, Martin Jönsson about the rights issue (Swedish)
| |
|
May 2, 2024
|
Interview at Finwire with Johan Sandin, CSO (Swedish)
| |
|
May 2, 2024
|
Rights issue presentation with CEO Martin Jönsson (Swedish)
| |
|
May 2, 2024
|
AlzeCure's CEO Martin Jönsson at Redeye (Swedish)
| |
|
April 11, 2024
|
CEO Martin Jönsson presenting at Finwire (Swedish)
| |
|
April 10, 2024
|
AlzeCure's CEO Martin Jönsson at Redeye's event on Alzheimer's (Swedish)
| |
|
March 21, 2024
|
AlzeCure presents new preclinical data with NeuroRestore ACD856 at leading Alzheimer’s conference, AD/PD 2024
|
|
|
March 7, 2024
|
Expert Event - Advances in the treatment of Alzheimer’s disease – Small molecule Gamma-Secretase Modulators (GSMs) as promising disease-modifying treatments together
|
|
|
February 19, 2024
|
Alzheimer’s disease and the amyloid hypothesis – Professor Henrik Zetterberg, MD, PhD, Gothenburg University & University College London, AlzeCure Pharma expert event
|
|
|
February 19, 2024
|
Alzstatin: a small molecule disease modifying and preventive therapy against Alzheimer’s – Johan Sandin, PhD, CSO, AlzeCure; AlzeCure Pharma expert event with Johan Sandin, PhD, CSO, AlzeCure
|
|
|
February 19, 2024
|
Welcome address, agenda & company overview, – Martin Jönsson, CEO, AlzeCure; AlzeCure Pharma expert event - Alzheimer’s around highly current gamma-secretase modulators
|
|
|
February 19, 2024
|